1. |
Vinholes J, Coleman R, Lacombe D, et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen crosslink exertion. European Organization for Research and Treatment of Cancer [J]. Br J Cancer, 1999; 80(1-2)∶221.
|
2. |
Fontana A, Delmas PD. Markers of bone turnover in bone metastases [J]. Cancer, 2000; 88(12 Suppl)∶2952.
|
3. |
Demers LM, Costa L, Chinchilli VM, et al. Biochemical markers of bone turnover in patients with metastatic bone disease [J]. Clin Chem, 1995; 41(10)∶1489.
|
4. |
Hou MF, Tsai LY, Tsai SM,et al. Biochemical markers for assessment of bone metastases in patients with breast cancer [J]. Kaohsiung J Med Sci, 1999; 15(8)∶452.
|
5. |
Clemens JD, Herrick MV, Singer FR, et al. Evidence that serum NTx(collagentype Ⅰ Ntelopeptides) can act as an immunochemical marker of bone resorption [J]. Clin Chem, 1997; 43(11)∶2058.
|
6. |
Wada N, Fujisaki M, Ishii S,et al. Evaluation of bone metabolic markers in breast cancer with bone metastasis [J]. Breast Cancer, 2001; 8(2)∶131.
|
7. |
Ulrich U, Rhiem K, Schmolling J, et al. Crosslinked type Ⅰ collagen C and Ntelopeptides in women with bone metastases from breast cancer [J]. Arch Gynecol Obstet, 2001; 264(4)∶186.
|
8. |
Kamby C, Egsmose C, Soletormos G, et al. The diagnostic and prognostic value of serum bone GLa protein(osteocalcin) in patients with recurrent breast cancer [J]. Scand J Clin Lab Invest, 1993; 53(5)∶439.
|
9. |
Keskikuru R, Kataja V, Kosma VM, et al. Preoperative high type Ⅰ collagen degradation marker ICTP reflects advanced breast cancer [J]. Anticancer Res, 1999; 19(5C)∶4481.
|
10. |
Shimozuma K, Sonoo H, Fukunaga M, et al. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a prcliminary report [J]. Jpn J Clin Oncol, 1999; 29(1)∶16.
|
11. |
Yamamoto I, Miura H, Kigami Y, et al. Detection of bone metastasis by serial measurement of Cterminal telopeptide of type Ⅰ collagen in patients with malignancy [J]. Kaku Igaku, 1996; 33(4)∶423.
|